Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Karolinska Development in connection with the company's listing on NASDAQ OMX
Mandate

Vinge advises Karolinska Development in connection with the company's listing on NASDAQ OMX

March 31, 2011

Vinge advises Karolinska Development AB (publ) in connection with the company’s new issue of shares of series B and listing of shares of series B on NASDAQ OMX Stockholm. First day of trading is expected to be 15 April 2011.

Vinge’s team consists of partner in charge Pontus Enquist as well as Emil Hedberg and Christoffer Benninge. In addition, Maria Schultzberg, Johanna Bergström and Maria Doeser (tax) as well as Claes Henriksson (IP), among other, have participated.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026